Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p<0.001), with improvement observed as early as Week 2 and maintained through Month 12
Covered in this story
Call it yourself
No calls on $TOP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TOP Financial Group →Dalsna Finance is currently tracking 26 stories mentioning TOP Financial Group, the earliest published 15 Jan 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.